Pharmacologic strategies for treatment-resistant OCD: A review of the evidence

Psychiatric Annals

Volumn 36, Issue 7, 2006, Pages 464-473

  Fineberg, Naomi A ^a,b,d   Nigam, Amit ^a,c   Sivakumaran, Thanusha ^a  

^a Hertforshire Partnership NHS Trust   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^d QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33746811477     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20060701-07     Document Type: Review

References (71)

1. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004; 24(8):1011-1030.
2. Treatment of obsessive-compulsive disorder. The Expert Consensus Panel for obsessive-compulsive disorder. J Clin Psychiatry. 1997;58(Suppl 4):2-72.
3. Greist JH, Bandelow B, Hollander E. et al.; World Council of Anxiety. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectr. 2003;8(8 Suppl 1):7-16.
4. Pallanti S, Hollander E, Bienstock C, et al.: International Treatment Refractory OCD Consortium. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol. 2002; 5(2):181-191.
5. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011.
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville. MD: US Department of Health Education and Welfare; 1976:217-222. Publication ADM.
7. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol. 2006;26(1):79-83.
8. Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry. 1997;58(Suppl 5):32-49.
9. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52(4):289-295.
10. Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess. 2001;5(16):1-69.
11. Mann T. Clinical Guidelines: Using Clinical Guidelines to Improve Patient Care Within the NHS. London, England: Department of Health: 1996.
12. th Annual Meeting of the American Psychiatric Association; May 17-22, 1997; San Diego. CA.
13. Ackerman DL, Greenland S Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol. 1998;18(3):185-192.
14. Koran LM. Hackett E, Rubin A, Wolkow R, Robinson. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002;159(1):88-95.
15. Hollander E, Friedberg J, Wasserman S, et al. Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003; 64(5):546-550.
16. Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry. 2004; 65(1):37-43.
17. Bejerot S, Bodlund O. Response to high doses of citalopram in treatment-resistant obsessive compulsive disorder. Acta Psychiatr Scand. 1998;98(5):423-424.
18. Byerly MJ, Goodman WK, Christensen R. High doses of sertraline for treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1996;153(9):1232-1233.
19. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry. 1991;48(8):730-738.
20. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry. 1998;55(10):918-924.
21. Pallanti S, Quercioli L, Koran LM. Citalopram infusions in resistant obsessive compulsive disorder: an open trial. J Clin Psychiatry. 2002;63(9):796-801.
22. McDougle CJ, Goodman WK, Price LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiat. 1990;147:652-654.
23. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51(4):302-308.
24. McDougle CJ, Walsh KH. Treatment for refractory OCD. In: Fineberg NA, Marazitti D, Stein D, eds. Obsessive Compulsive Disorder: A Practical Guide. London, England: Martin Dunitz; 2001.
25. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry. 2000;57(8):794-801.
26. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2003;6(4):397-401.
27. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment for obsessive compulsive disorder: a double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2005;15(1):69-74.
28. Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive compulsive disorder: a single blind, placebo-controlled study. Int Clin Psychopharmacol. 2002;17(3):115-119.
29. Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004;65(8):1040-1048.
30. Fineberg NA, Sivakumarun T, Roberts A. Gale T. Adding quetiapine to SRI in treatment-resistant obsessive compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005;20(4):223-226.
31. Carey PD, Vythilingum B, Seedat S, et al. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. BMC Psychiatry. 2005;5(1):5.
32. Fineberg NA, Stein DJ, Premkumar P, et al. Adjunctive quetiapine for SRI-resistant obsessive compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol. In press.
33. Bystritsky A, Ackerman DL, Rosen R, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry. 2004; 65(4):565-568.
34. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry. 2004;55(5):553-563.
35. Metin O, Yazici K, Tot S, Yazici AE. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial. Hum Psychopharmacol. 2003;18(6):463-467.
36. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. Systematic review: antipsychotic augmentation for treatment-refractory OCD. Presented at: American College of Neuropsychopharmacology 44th Annual Meeting December 11-15, 2005; Waikoloa, Hawaii.
37. Maina G, Albert U, Ziero S, Bogetto F. Antipsychotic augmentation for treatment-resistant obsessive compulsive disorder: what if antipsychotic is discontinued? Int Clin Psychopharmacol. 2003;18(1):23-28.
38. McDougle CJ, Barr LC, Goodman WK, et al. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry. 1995;152(12):423-429.
39. Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry. 2005;66(1):49-51.
40. Sareen J, Kirshner A, Lander M, et al. Do antipsychotics ameliorate or exacerbate obsessive compulsive disorder? A systematic review. J Affective Disorders. 2004;82(2):167-174.
41. Poyurovsky M, Koran L. Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res. 2005;39(4):399-408.
42. Szegedi A, Wetzel H, Leal M, Hartter S, Hiemke C. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry. 1996;57(6):257-264.
43. Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiat. 1999; 14(2):101-106.
44. Pigott TA, L'Heureux F, Hill JL, et al. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive compulsive disorder. J Clin Psychopharmacol. 1992;12(3):11-18.
45. McDougle CJ, Goodman WK, Leckman JF, et al. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry. 1993;150(4):647-649.
46. Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry. 1993;150(5):819-821.
47. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive compulsive disorder. J Clin Psychopharmacol. 1991;11(4):242-248.
48. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive compulsive disorder: lack of efficacy. J Clin Psychopharmacol. 1991;11(3):175-184.
49. Hollander E, Kaplan A, Stahl SM. A double-blind placebo-controlled trial of clonazepam in obsessive-compulsive disorder. World J Biol Psychiatry. 2003;4(1):30-34.
50. th Annual Meeting of the American Psychiatric Association; May 2-7, 1992; Washington DC.
51. Practice guideline for the treatment of patients with panic disorder. Work Group on Panic Disorder. American Psychiatric Association. Am J Psychiatry. 1998;155(5 Suppl):1-34.
52. Practice guideline for the treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. In press.
53. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol. 2000;10(3):165-169.
54. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fiuvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998;13(5):219-224.
55. Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol. 1996;11(1):37-44.
56. Noorbala AA, Hosseini SH, Mohammadi MR, Akhondzadeh S. Combination of clomipramine and nortriptyline in the treatment of obsessive-compulsive disorder: a double-blind, placebo-controlled trial. J Clin Pharm Ther. 1998;23(2):155-159.
57. Barr LC, Goodman WK, Anand A, McDougle CJ, Price LH. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Am J Psychiatry. 1997;154(9):1293-1295.
58. Levine J. Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol. 1997;7(2):147-155.
59. Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmacol. 1999;2(3):193-195.
60. Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol. 1999;14(6):353-356.
61. Zohar J, Kennedy JL, Hollander E, Koran LM. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update. J Clin Psychiatry. 2004;65(Suppl 14):18-21.
62. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol. 2001;11(2):169-172.
63. Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(9):480-481.
64. Sporn J, Smith M, Jersino JM, et al. A double-blind, placebo-controlled trial of gabapentin (GBP) augmentation of fluoxetine for treatment of obsessive-compulsive disorder (OCD). Presented at: New Clinical Drug Evaluation Unit Program; May 28-31, 2001; Phoenix, AZ.
65. Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2005;66(3):353-359.
66. Insel TR, Hamilton JA, Guttmacher LB, Murphy DL. D-amphetamine in obsessive-compulsive disorder. Psychopharmacology (Berl). 1983;80(3):231-235.
67. Joffe RT, Swinson RP, Levitt AJ. Acute psychostimulant challenge in primary obsessive-compulsive disorder. J Clin Psychopharmacol. 1991;11(4):237-241.
68. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev. 2005;29(3):399-419.
69. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl). 2003;167(2):219-220.
70. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424-428.
71. Sequenced treatment algorithms for resistant OCD: an international approach. Presented at: 2005 American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta GA.